Drugs / Ringers acetate solution
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02560519 Comparator | Mar 2017 → Apr 2020 | — | Helsinki University Central Hospital | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ringers acetate solution | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02560519 ↗ |
| Modality | Other / unclassified | “Crystalloid solutions, such as Ringer's acetate, do not impair neither renal function nor coagulation” NCT02560519 ↗ |
| Route | Intravenous | “4% albumin solution compared with Ringer acetate as cardiopulmonary bypass prime and perioperative intravenous volume replacement solution” PMID 35852528 ↗ Jul 2022 |